Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;41(1):126-133.
doi: 10.1038/s41372-020-00824-7. Epub 2020 Sep 19.

Use of vasopressin in neonatal hypertrophic obstructive cardiomyopathy: case series

Stephanie M Boyd  1   2 , Kristin L Riley  3 , Regan E Giesinger  1   3 , Patrick J McNamara  4   5
Affiliations

Use of vasopressin in neonatal hypertrophic obstructive cardiomyopathy: case series

Stephanie M Boyd et al. J Perinatol. 2021 Jan.

Abstract

Objective: To determine the effect of vasopressin on arterial blood pressure in infants with neonatal hypertrophic obstructive cardiomyopathy (HOCM).

Study design: Retrospective case study in Neonatal ICU involving six infants; five born to mothers with diabetes mellitus (mean gestational age 37.5 ± 0.9 weeks). Vasopressin infusion was started at a mean dose of 0.3 ± 0.2 mU/kg/min.

Result: Initiation of vasopressin was followed by improved mean (p = 0.004), systolic (p = 0.028), and diastolic (p = 0.009) arterial pressure within 2 h. Heart rate (p = 0.025) and oxygen requirement (p = 0.021) also declined after initiation. Serum sodium declined initially and recovered by 72 h (p = 0.017).

Conclusion: Although there is limited experience with vasopressin use in neonatal HOCM, our case series suggests it may be beneficial for improving systemic hypotension and stabilization of hemodynamics. The potential for hyponatremia is high, necessitating careful fluid/electrolyte management. A prospective randomized trial is necessary to confirm safety and efficacy of vasopressin treatment in neonatal HOCM.

PubMed Disclaimer

Comment in

References

    1. Henry W, Clark CE, Epstein SE. Asymmetric septal hypertrophy; echocardiographic identification of the pathognomonic anatomic abnormality of IHSS. Circulation. 1973;47:25–33.
    1. Zielinsky P, Piccoli AL Jr. Myocardial hypertrophy and dysfunction in maternal diabetes. Early Hum Dev. 2012;88:273–8. - PubMed
    1. Halliday H. Hypertrophic cardiomyopathy in infants of poorly-controlled diabetic mothers. Arch Dis Child. 1981;56:258–63. - PubMed - PMC
    1. Mormile R. Neonate of diabetic mothers: the starting point for developing novel therapeutic approaches to the ischemic heart and brain? Med Hypotheses. 2016;96:75–7. - PubMed
    1. Franzese A, Valerio G, Cicarelli NP, De Filippo G, Iannucci MP, Alfonsi L, et al. Severe hypertrophic cardiomyopathy in an infant of a diabetic mother. Diabetes Care. 1997;20:676–7. - PubMed

LinkOut - more resources